David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
News|Articles|September 3, 2026
SPECTRUM: Early Clinical Data and Practice Experience From Global Real-World Study of Intravitreal Aflibercept (EYLEA®, Bayer AG) 8mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Advertisement
SPECTRUM: Early Clinical Data and Practice Experience From Global Real-World Study of Intravitreal Aflibercept (EYLEA®, Bayer AG) 8mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Presentation highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting
Advertisement
Related to this article
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.
OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Varicose veins linked to central serous chorioretinopathy in large cohort study
3
Uveitis: a practical guide for ophthalmologists and optometrists
4
FDA approves subcutaneous Enspryng for TED
5